Exelixis, Inc. (NASDAQ:EXEL) Director Sells $331,430.40 in Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Jack L. Wyszomierski sold 8,768 shares of the firm’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares of the company’s stock, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Exelixis Trading Up 2.8 %

Exelixis stock opened at $38.69 on Friday. The firm has a market cap of $10.83 billion, a P/E ratio of 21.86, a P/E/G ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $38.72. The firm has a 50-day moving average of $34.53 and a 200-day moving average of $31.66.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on EXEL. Piper Sandler upped their price target on shares of Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Citigroup raised their target price on Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Truist Financial lifted their price target on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a report on Monday, January 27th. Stifel Nicolaus upped their target price on Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a report on Wednesday, February 12th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Exelixis in a research report on Thursday, February 13th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.24.

Institutional Trading of Exelixis

Several large investors have recently added to or reduced their stakes in EXEL. Coppell Advisory Solutions LLC bought a new position in Exelixis in the 4th quarter worth $25,000. Colonial Trust Co SC increased its position in shares of Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 765 shares during the period. USA Financial Formulas purchased a new position in shares of Exelixis during the fourth quarter valued at about $32,000. Principal Securities Inc. raised its stake in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after buying an additional 373 shares in the last quarter. Finally, Kestra Investment Management LLC purchased a new stake in Exelixis in the fourth quarter worth about $39,000. Institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.